TY - JOUR
T1 - Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients
T2 - How prognostic classification impact treatment decisions
AU - Iacovelli, Roberto
AU - Ciccarese, Chiara
AU - Schinzari, Giovanni
AU - Maiorano, Brigida Anna
AU - Rossi, Ernesto
AU - Pierconti, Francesco
AU - Bassi, Pier Francesco
AU - Bria, Emilio
AU - Tortora, Giampaolo
N1 - Copyright © 2019 Elsevier B.V. All rights reserved.
PY - 2019/7
Y1 - 2019/7
N2 - De-novo metastatic castration sensitive prostate cancer (mCSPC) is a subgroup of prostate cancer associated with poor prognosis. Recently, the treatment of mCSPC has been enriched by new life-prolonging options, including the combination of docetaxel or abiraterone acetate with androgen deprivation therapy (ADT). Of note, the advantage of chemohormonal therapy was more relevant in the subgroup of high-volume disease compared to low-volume, while the survival prolongation of abiraterone was observed only in high-risk patients. Choosing the most appropriate therapy is one of the most debated issues. This review describes the latest news on de-novo mCSPC to better outline patients' management. At the ESMO 2018 Congress two novel studies focused on this setting have been presented, trying to define the role of radiotherapy to the primary tumour and the efficacy of abiraterone acetate in the subset of low-risk patients. We have analysed these results in light of the evidence already available.
AB - De-novo metastatic castration sensitive prostate cancer (mCSPC) is a subgroup of prostate cancer associated with poor prognosis. Recently, the treatment of mCSPC has been enriched by new life-prolonging options, including the combination of docetaxel or abiraterone acetate with androgen deprivation therapy (ADT). Of note, the advantage of chemohormonal therapy was more relevant in the subgroup of high-volume disease compared to low-volume, while the survival prolongation of abiraterone was observed only in high-risk patients. Choosing the most appropriate therapy is one of the most debated issues. This review describes the latest news on de-novo mCSPC to better outline patients' management. At the ESMO 2018 Congress two novel studies focused on this setting have been presented, trying to define the role of radiotherapy to the primary tumour and the efficacy of abiraterone acetate in the subset of low-risk patients. We have analysed these results in light of the evidence already available.
KW - Combined Modality Therapy
KW - Disease Management
KW - Humans
KW - Male
KW - Patient Selection
KW - Prognosis
KW - Prostatic Neoplasms, Castration-Resistant/classification
U2 - 10.1016/j.critrevonc.2019.05.005
DO - 10.1016/j.critrevonc.2019.05.005
M3 - Review article
C2 - 31112886
VL - 139
SP - 83
EP - 86
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
ER -